94b2af92-0cfc-40b2-977d-6bd0fa4440d9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- INFLAMMATORY_RESPONSE+0.500
- COMPLEMENT+0.400
- TNFA_SIGNALING_VIA_NFKB+0.300
- IL2_STAT5_SIGNALING+0.200
- KRAS_SIGNALING_UP+0.200
- APOPTOSIS+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.500
- DNA_REPAIR-0.400
- MITOTIC_SPINDLE-0.400
- NOTCH_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- ADIPOGENESIS-0.300
- GLYCOLYSIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518255 | — | D | 0.937 |
| 2 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.910 |
| 3 | ff12dc45-d7ab-45ae-a049-2d20e3c546b6 | — | — | 0.909 |
| 4 | 3c5fe4dc-8606-4615-994f-c41861f08f5a | — | — | 0.892 |
| 5 | 39927c92-75d7-424c-9bcd-63def0075a1d | — | — | 0.887 |
| 6 | 3a2b80a5-6937-423a-92bf-9e25a0b23c5b | — | — | 0.878 |
| 7 | d24acd56-d148-487c-8d44-b303a68eb9d2 | — | — | 0.875 |
| 8 | TCGA-MP-A4TJ-01A-51R-A262-07 | — | cohortA1 | 0.874 |
| 9 | TCGA-55-6987-01A-11R-1949-07 | — | cohortMD2 | 0.872 |
| 10 | SRR8518215 | — | D | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |